“Cancer Sleuths Uncovering DNA Mysteries for Novartis, Glaxo” - Dr. Lewis Silverman
Research over the last decade has found that defects in so-called epigenetic control molecules may be as important a cause of cancer as direct DNA damage. Lewis Silverman, a hematologist at New York’s Mount Sinai School of Medicine tested 5-azacytidine, the drug that would become Vidaza, in patients with myelodysplastic syndrome. The drug had been rejected by U.S. regulators for treating acute leukemia. Silverman used lower doses to reprogram the cells without killing them. Learn more
Mount Sinai’s Staten Island Cancer Center Moves to New Site
Nov 09, 2023 View All Press Releases
Researchers Find Treatment Options for Patients Whose Blood Cancer Relapses After CAR-T
Nov 04, 2022 View All Press Releases
Study Identifies New Gene That Drives Colon Cancer
Oct 14, 2022 View All Press Releases
Mount Sinai Receives Grant to Enhance Patient-Centric, Team-Based Pancreatic Cancer Care
Apr 19, 2022 View All Press Releases